Boston Scientific appoints COO. Boston Scientific stock costs EUR 40.33 at USD 65.3 billion value

Published on 10/20/2026 at 10:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Three reportable segments are planned from January 1, 2027. Boston Scientific stock costs EUR 40.33 on October 20, 2026, with USD 65.3 billion value.

Leadership and reporting dates

Boston Scientific announced Joseph M. Fitzgerald as COO on October 7, 2026, effective January 1, 2027.
Second-quarter 2026 revenue reached USD 5.44 billion, up 7.50 percent year over year.
Boston Scientific stock traded at EUR 40.33 at 10:48 a.m. CEST at Lang & Schwarz on October 20, 2026.
Mark Bickel is scheduled to become chief accounting officer on March 1, 2027.

Isometrisches 3D-Diagramm der REIT-Wertschöpfungskette mit Bürogebäude, Mietern und Investoren — Boston Properties US1011371077 visualisiert die Immobilien-REIT-Wertschöpfungskette isometrisch mit Mietern, Investoren und Verwaltern, Illustration mit AI erstellt.

Boston Scientific (ISIN US1011371077) appointed Joseph M. Fitzgerald as executive vice president and chief operating officer on October 7, 2026, effective January 1, 2027. The company also plans three reportable segments, giving the leadership change a direct operating consequence.

Leadership change and three segments

According to Boston Scientific, Fitzgerald will oversee global operations, business units and regions. The new structure will comprise Interventional Therapies, Rhythm Solutions and MedSurg from January 1, 2027.

The reorganization follows a second quarter in which Boston Scientific generated USD 5.44 billion of revenue, up 7.50 percent from USD 5.06 billion in the same quarter of 2025, according to MarketBeat. Adjusted earnings per share were USD 0.86, above the USD 0.83 consensus estimate, while full-year 2026 adjusted earnings-per-share guidance stood at USD 3.28 to USD 3.32.

What does the structure change mean?

Fitzgerald's remit connects the leadership move with portfolio allocation and decision-making rather than only personnel succession. The three-segment design is scheduled to take effect on the same January 1, 2027 date as his promotion, creating a single operational reset.

Three dated steps for Boston Scientific

On July 29, 2026, Boston Scientific reported USD 5.44 billion in second-quarter revenue. On October 1, 2026, the company appointed Mark Bickel as chief accounting officer effective March 1, 2027. On October 7, 2026, it appointed Fitzgerald as COO effective January 1, 2027, as documented in the company's SEC filing.

Next executive dates

The next scheduled management milestones are January 1, 2027, when Fitzgerald's COO role and the three-segment structure begin, and March 1, 2027, when Bickel is due to become chief accounting officer.

Stock and valuation context

Boston Scientific stock was trading at EUR 40.33 at Lang & Schwarz on October 20, 2026, at 10:48 a.m. CEST. The company's primary listing is on the New York Stock Exchange, where the stock was last quoted at USD 45.05 on October 19, 2026 at 4:00 p.m. EDT; its market capitalization was USD 65.3 billion and its 52-week range was USD 41.39 to USD 105.65.

The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.